- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: P fimbriae.
Displaying page 1 of 1.
| EudraCT Number: 2022-002697-80 | Sponsor Protocol Number: MADI-02 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Université Libre de Bruxelles | ||
| Full Title: Maternal determinants of infant immunity to pertussis | ||
| Medical condition: Vaccination against whooping cough in non-pregnant women and in pregnant women. Vaccination against whooping cough in the Belgian vaccination program in children from 2 months of age | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-005842-69 | Sponsor Protocol Number: Td526 | Start Date*: 2016-01-26 | |||||||||||||||||||||
| Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||
| Full Title: Immune Responses in Adults to Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose | |||||||||||||||||||||||
| Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2016-000274-37 | Sponsor Protocol Number: PRI03C | Start Date*: 2016-03-21 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:MCM Vaccine B.V. | ||||||||||||||||||||||||||||||||||||||
| Full Title: Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 year old Children Previously Vaccinated with a 2-dose or 3-dose Infants series and Toddler dose with VAXELIS... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Vaxelis is indicated for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis and invasive diseases caused by Haemophilus ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FI (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-003923-17 | Sponsor Protocol Number: SH600008 | Start Date*: 2023-01-26 | ||||||||||||||||
| Sponsor Name:Sanofi Pasteur | ||||||||||||||||||
| Full Title: Safety and Immunogenicity Study of Full Schedule (3-Dose of Shan6™) or Shan6™-Shan5®-Shan6™ Versus the Licensed Vaccine Shan5® With bOPV (bivalent oral polio vaccine) and IPV (inactivated poliomyel... | ||||||||||||||||||
| Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-002452-40 | Sponsor Protocol Number: Td500056 | Start Date*: 2023-03-08 | ||||||||||||||||||||||||||
| Sponsor Name:Sanofi Pasteur | ||||||||||||||||||||||||||||
| Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg... | ||||||||||||||||||||||||||||
| Medical condition: Bacterial infections | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-002988-10 | Sponsor Protocol Number: 212645 | Start Date*: 2021-02-09 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals SA | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK’s Infanrix hexa (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV’s Vaxelis (DTaP5-HBV-... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Healthy volunteers [Primary and booster immunization of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-004095-10 | Sponsor Protocol Number: V419-005 | Start Date*: 2012-02-20 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Sanofi Pasteur Limited | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Conco... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-021068-13 | Sponsor Protocol Number: RPV03C | Start Date*: 2010-08-31 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Sanofi Pasteur MSD S.N.C. | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Repevax: Antibodies response to Diphtheria Toxoid ,Tetanus Toxoid, Pertussis Toxoid*, Filamentous Haemagglutinin, Pertactin, Fimbriae Types 2 and 3, Poliomyelitis Virus Type 1, Poliomyelitis Virus ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-005273-31 | Sponsor Protocol Number: HPARSRSG12/06 | Start Date*: 2013-05-30 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Public Health England | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Menin... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Prevention of meningitis C and pertussis | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-004495-34 | Sponsor Protocol Number: iMAP2 | Start Date*: 2014-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Public Health England | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A randomised controlled trial comparing two pertussis-containing vaccines in pregnancy and vaccine responses in UK mothers and their infants (immunising Mums Against Pertussis, iMAP2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: No medical condition or disease, instead responses to immunisations against pertussis (whooping cough) in mothers and against pertussis (whooping cough), tetanus, diphtheria, Hib, meningococcal C a... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.